Roche's Rituxan now is the first and only FDA approved treatment for pediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis.
SB 159 authorizes pharmacists to prescribe PrEP and PEP to patient without a physician prescription and prohibits insurance companies from requiring patients to obtain prior authorization before using their insurance benefits to obtain PrEP or PEP.
